Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Mohnish Pabrai, Dalal Street Keep Buying Horshead Holding Corp Shares

Mohnish Pabrai is still bullish on HORSEHEAD HOLDING CORP. (NASDAQ:ZINC), which can be concluded from the latest filing by Dalal Street with the Securities and Exchange Commission. Dalal Street reported purchasing some 147,100 shares of the company. The fund spent a total of $2.1 million shares to increase its holding in the company to over 6.4 million shares.


As we have mentioned it earlier, Mr. Pabrai has been buying shares of Horshead for a while now. In its latest 13F, in which Dalal Street reported its equity portfolio as at the end of the third quarter, the fund disclosed holding just around 5.1 million shares of the company. At the same time, the fund has been long Horsehead for a couple of years, the earliest mentioning of the stake in the company appearing in the 13F filing for the third quarter of 2012, Dalal revealed ownership of some 1.8 million shares of the company.

The stock of Horsehead is trailing a forward P/E of over 18, and shows a year-to-date return of almost 40%. The company has an expected EPS increase of over 400% for the next year. In the third quarter, the company reduced its net loss to $3.5 million, or $0.08 per diluted share from $9.1 million in the same period of last year. The company is also conducting some projects to increase its productivity of zinc, building a facility in North Carolina, which is expected to begin its activity by the end of the year. This project is of a particular value for the company since its expected to deliver earnings between $90 and $110 million, amid costs of $490 million.

Chuck Royce’s hedge fund Royce & Associates, in its latest 13F filing disclosed holding around 4.1 million shares of the company, reducing the position by some 432,600 shares.

Disclosure: none

Recommended Reading:

Dan Loeb, Third Point Buy Shares of Enphase Energy at $6.83 Per Share

Karpus Management To Nominate Three Directors to Western Asset Inflation Management Fund’s Board

Corvex Capital, Related Fund Management to Nominate New Board of Trustees at CommonWealth REIT


Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!